Garcia Marino insider trades
Garcia Marino has filed 9 Form 4s with the SEC that we hold, for Dianthus Therapeutics, Inc. /DE/ (DNTH) (CEO AND PRESIDENT, Director) and AgomAb Therapeutics NV (AGMB) (Director). Across all of them we count 0 purchases worth $0 and 12 sales worth $28.0M reported on Form 4. In the last 12 months: 0 purchases ($0) and 12 sales ($28.0M). The largest single trade was a sale of 104,091 shares of Dianthus Therapeutics, Inc. /DE/ worth $11.2M, dated 2026-08-07. The first filing on our record is dated 2024-01-26 and the latest 2026-09-15.
Dianthus Therapeutics, Inc. /DE/ (DNTH)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-03-12 | S, sale reported on Form 4 | 65,517 | $5.4M | 2026-03-13 |
| 2026-03-12 | S, sale reported on Form 4 | 43,505 | $3.5M | 2026-03-13 |
| 2026-03-12 | S, sale reported on Form 4 | 12,796 | $1.1M | 2026-03-13 |
| 2026-03-12 | S, sale reported on Form 4 | 200 | $16.7K | 2026-03-13 |
| 2026-03-12 | S, sale reported on Form 4 | 900 | $77.0K | 2026-03-13 |
| 2026-08-07 | S, sale reported on Form 4 | 10,384 | $1.1M | 2026-08-07 |
| 2026-08-07 | S, sale reported on Form 4 | 23,907 | $2.6M | 2026-08-07 |
| 2026-08-07 | S, sale reported on Form 4 | 2,373 | $258.9K | 2026-08-07 |
| 2026-08-07 | S, sale reported on Form 4 | 2,536 | $279.0K | 2026-08-07 |
| 2026-08-07 | S, sale reported on Form 4 | 800 | $88.6K | 2026-08-07 |
| 2026-08-07 | S, sale reported on Form 4 | 104,091 | $11.2M | 2026-08-07 |
| 2026-08-07 | S, sale reported on Form 4 | 21,909 | $2.4M | 2026-08-07 |
AgomAb Therapeutics NV (AGMB)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1669866) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms